7 recruiting, 2 active not recruiting, 2 not yet recruiting. 11 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 7, Active not recruiting 2, Not yet recruiting 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Nemtabrutinib: new trials by email Literature Review of Nemtabrutinib trials Research Report on Nemtabrutinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Nemtabrutinib, Lisocabtagene Maraleucel - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2026-12-01 | 2026-10-29 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor Nemtabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | Phase 2 | Not yet recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 32 | 2026-11-12 | 2026-11-09 |
| Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Jennifer Woyach | 25 | 2026-11-01 | 2026-10-15 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Nemtabrutinib, Venetoclax, Obinutuzumab - Chronic Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Medical College of Wisconsin | 30 | 2026-10-01 | 2026-07-08 |
| Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma Nemtabrutinib, Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus) - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-07-31 | 2026-08-17 |
| Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Nemtabrutinib - Mantle Cell Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 27 | 2025-01-22 | 2026-03-13 |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) Zilovertamab vedotin, Nemtabrutinib - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 189 | 2022-07-21 | 2026-08-21 |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) Nemtabrutinib - Hematologic Malignancies, Waldenstroms Macroglobulinaemia | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 490 | 2021-04-05 | 2026-10-27 |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) Nemtabrutinib - Lymphoma, B-Cell, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Active not recruiting | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 190 | 2017-06-26 | 2026-06-12 |
Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, Mantle-Cell (4) · Hematologic Neoplasms (2) · Leukemia, B-Cell (2) · Lymphoma (2) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Recurrence (2) · Waldenstrom Macroglobulinemia (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hemorrhagic Disorders (1)
City of Hope Medical Center (2) · Merck Sharp & Dohme LLC (2) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (1) · Fred Hutchinson Cancer Center (1) · Jennifer Woyach (1) · Medical College of Wisconsin (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Roswell Park Cancer Institute (1) · Vanderbilt-Ingram Cancer Center (1)
United States (11) · Brazil (2) · Canada (2) · China (2) · Czechia (2) · Germany (2) · Ireland (2) · Israel (2) · Italy (2) · Poland (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Argentina (1)
Alexey V Danilov (1) · Bhagirathbhai Dholaria (1) · Geoffrey Shouse (1) · Guru S Guru Murthy, MD (1) · Jennifer A Woyach, MD (1) · Jennifer Huang, MD, PhD (1) · Laura S Samples, M.D. (1) · Matthew J Cortese (1)
P30CA033572 (2), 2023 (1)